CoChat
Sign Up
Cited by 328Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study

Open access
Schrijvers, E.M.C., Witteman, J.C.M., Sijbrands, E.J.G., Hofman, A., Koudstaal, P.J., Breteler, M.M.B.·2010·Neurology
DOI 10.1212/wnl.0b013e3181ffe4f6PMC PMC3014236
Open this paper in CoChat — free account

Abstract

OBJECTIVE: Diabetes mellitus has been associated with an increased risk of Alzheimer disease (AD), but how it exerts its effect remains controversial. Possible pathophysiologic mechanisms are glucose toxicity and a direct effect of insulin on amyloid metabolism. Most studies had short follow-up, and longer-term effects of diabetes on AD risk are unknown. We investigated whether fasting glucose and insulin levels and insulin resistance are associated with the risk of AD and whether this risk is constant over time. METHODS: The study was based on 3,139 participants of the Rotterdam Study, a population-based cohort study. All subjects were free from dementia, did not have a history of diabetes, and had fasting levels of glucose and insulin measured at baseline. Insulin resistance was estimated with the homeostasis model assessment. We investigated how fasting glucose, insulin, and insulin resistance are related to the risk of AD in 3 different strata according to time-to-event, using Cox proportional hazards models. RESULTS: During follow-up, 211 participants developed AD, 71 of them within 3 years of baseline. Levels of insulin and insulin resistance were associated with a higher risk of AD within 3 years of baseline. After 3 years, the risk was no longer increased. Glucose was not associated with a higher risk of AD. There was no interaction of APOE ε4 carriership and insulin metabolism on the risk of AD. CONCLUSIONS: Our findings suggest that insulin metabolism influences the clinical manifestation of AD only within 3 years.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3181ffe4f6

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Rothman KJ. Measuring interactions. In: Epidemiology: An Introduction. New York:Oxford University Press; 2002:168–180

Cited by

Sorted by citations

See all 328

Related

Metadata

Authors
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B.
Affiliations
  • Erasmus MC (NL)
  • From the Departments of Epidemiology (E.M.C.S., J.C.M.W., A.H., M.M.B.B.), Neurology (E.M.C.S., P.J.K.), and Internal Medicine (E.J.G.S.), Erasmus MC University Medical Center, Rotterdam, the Netherlands.
ORCID
Venue
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2010-11-30
Volume
75
Issue
22
Pages
1982-1987
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
DOI
10.1212/wnl.0b013e3181ffe4f6
PMC
PMC3014236
OpenAlex
W2084979315
Cited by
328
References
40
Citations by year
2026: 7 · 2025: 14 · 2024: 14 · 2023: 19 · 2022: 16 · 2021: 25 · 2020: 26 · 2019: 20 · 2018: 25 · 2017: 33 · 2016: 23 · 2015: 21 · 2014: 26 · 2013: 19 · 2012: 24
FWCI
12.68
Type
journal article
Language
en
Open access
Locations
  • Neurology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
Funders
National Institute on Aging (R01AG033193)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
Alzheimer's disease, insulin metabolism, insulin resistance, fasting insulin, fasting blood glucose, diabetes mellitus, APOE ε4, amyloid metabolism, glucotoxicity, disease onset timing, Rotterdam Study
MeSH terms
Aged, Aged, 80 and over, Alleles, Alzheimer Disease, Blood Glucose, Female, Genotype, Humans, Insulin, Insulin Resistance, Male, Middle Aged, Risk, Cohort Studies, Proportional Hazards Models, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review